KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)
← Back to LibraryGHK-Cu, BPC-157, KPV, and thymosin-related component research.
Research Summary
- Evidence
- Very limited for the exact blend
- Primary research
- Separate component research; no established clinical regimen for the finished blend.
- Research focus
- GHK-Cu, BPC-157, KPV, and thymosin-related component research.
- Mechanism
- A four-component community/vendor blend.
- Evidence limits
- Component evidence does not validate the combination, and the exact thymosin ingredient must be confirmed.
How KLOW (BPC-157 + TB-500 + KPV + GHK-Cu) works in the body
A multi-peptide repair blend used in soft-tissue recovery contexts.
Muscle (Anecdotal / blend)
Used for muscle and soft-tissue recovery; combines repair-signaling peptides.
Tendon & ligament (Anecdotal / blend)
Directed at tendon and ligament repair. No independent human verification.
Educational only, not medical advice. Labels describe the type of research behind each area, not a recommendation.
Dosing evidence
Dose at a glance
| Item | Status |
|---|---|
| Composition | GHK-Cu + BPC-157 + KPV + thymosin-related peptide blend |
| Evidence | Very limited for the exact blend |
| Route | SC in community protocols; no clinically validated KLOW route |
| Common community formulation | 50/10/10/10 mg, 80 mg total |
| Common community dose example | 3.2 mg total blend |
| At that ratio | 2 mg GHK-Cu + 400 mcg each of BPC-157, KPV and the thymosin component |
| Clinically validated dose | None |
| Timing | No evidence-based timing requirement |
| Cycle | No clinically established cycle |
| Pre-mixed | Formulation-dependent; common community KLOW products are sold as fixed-ratio single-vial blends |
| FDA approved | No |
Exact formula and identity
KLOW is not a standardized drug name. The exact formulation needs to be confirmed before a protocol can be interpreted: GHK-Cu (mg), BPC-157 (mg), KPV (mg), the thymosin component (mg), and whether that thymosin component is full-length thymosin β4 or the TB-500 fragment. The common community formulation is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg KPV + 10 mg thymosin/TB component, 80 mg in total.
Community dose
For the common 50/10/10/10 formulation, the common community dose example is 3.2 mg of total blend, which contains:
- 2 mg GHK-Cu
- 400 mcg BPC-157
- 400 mcg KPV
- 400 mcg thymosin/TB component
This is a community-derived dose, not a clinically validated KLOW treatment dose. Community sources do not agree on one dose: PeptideFox uses 3.2 mg as a standard community example within a broader 1.6 to 4.8 mg range, while PeptideDosages publishes substantially lower total-blend examples. No single community dose is clinically established.
Community protocol examples
| Protocol | Schedule | Classification |
|---|---|---|
| Common community example | 3.2 mg daily, 5 days on / 2 days off, for 8 weeks | No human study has established daily dosing, 5 days on / 2 days off, an 8-week cycle or this dose as the optimal KLOW protocol. |
| PeptideFox community framework | Weeks 1 to 4: daily; weeks 5 to 8: 5 times per week; weeks 9 to 12: 2 to 3 times per week | Community / practitioner framework, not a clinically validated KLOW schedule. |
| Titration example | 2 mg, then 4 mg, then 6 mg, then 4 mg | Community protocol with no matching human dose-finding study identified. |
Weekend breaks and copper
Some community KLOW protocols use weekday dosing followed by weekend breaks. No human study shows that two days off prevent or meaningfully reduce copper accumulation or toxicity, so 5 days on / 2 days off is not established copper-sparing pharmacology. A weekend break is a community convention.
Zinc
There is no established evidence that subcutaneous GHK-Cu requires routine zinc supplementation because of intestinal zinc competition. Routine KLOW-specific zinc testing, mandatory 15 to 30 mg/day zinc supplementation, zinc deficiency as a KLOW contraindication and progressive zinc depletion as a KLOW side effect are all unsupported. The familiar zinc-copper interaction concerns intestinal absorption, particularly high oral zinc reducing copper absorption; that does not establish the reverse effect for subcutaneous GHK-Cu.
Protocol logic check
| Question | Verdict |
|---|---|
| Is KLOW a standardized FDA-approved drug? | No |
| Is 50/10/10/10 a documented community formulation? | Yes |
| Is every KLOW vial necessarily that formulation? | No |
| Must the exact thymosin component be confirmed? | Yes |
| Are full-length Tβ4 and TB-500 LKKTETQ interchangeable? | No |
| Human trial of the exact KLOW blend identified? | No |
| Is 3.2 mg mathematically coherent for 50/10/10/10? | Yes |
| Is 3.2 mg clinically validated? | No |
| Is daily dosing clinically validated? | No |
| Is 5 days on / 2 days off clinically validated? | No |
| Does a weekend break prevent copper toxicity? | Not established |
| Is an 8- or 12-week cycle required? | No |
| Does KLOW require receptor resetting? | No evidence |
| Does injected GHK-Cu require mandatory zinc? | No |
| Does KPV have meaningful preclinical anti-inflammatory evidence? | Yes |
| Did FDA identify human KPV exposure data? | No |
| Is KPV's human SC dose established? | No |
| Does BPC-157 have substantial human evidence? | No |
| Does full-length Tβ4 have some human evidence? | Yes |
| Does that validate TB-500 LKKTETQ? | No |
| Does GHK-Cu have legitimate component evidence? | Yes |
| Is injectable GHK-Cu safety well established? | No |
| Is "dopamine buffer" validated? | No |
| Is active malignancy an official KLOW contraindication? | No |
| Is same-vial stability established? | No |
| Is universal post-reconstitution stability established? | No |
Medical literature and study context
TB-500 versus full-length thymosin β4
PeptideFox describes its KLOW framework as containing full-length thymosin β4, while PeptideDosages labels its 80 mg formulation as containing TB-500. These labels do not necessarily describe the same molecule. Full-length thymosin β4 and the TB-500 fragment are not interchangeable, and human evidence for full-length thymosin β4 cannot be transferred to a TB-500 fragment product. FDA defines the TB-500 it reviewed as the LKKTETQ thymosin β4 fragment and reports no identified human exposure data for drug products containing it.
- Full-length thymosin β4: limited but real human evidence, largely in route- and formulation-specific wound research.
- TB-500 LKKTETQ: FDA reports no identified human exposure data for drug products containing the fragment.
- KLOW thymosin evidence: depends on which molecule is actually present.
KPV
KPV (Lys-Pro-Val) is a three-amino-acid peptide related to the C-terminal region of alpha-MSH. It has meaningful laboratory and animal evidence of anti-inflammatory activity, and experimental intestinal models support PepT1-related transport and effects on inflammatory signaling such as NF-κB-related pathways.
FDA's 2026 KPV review is the key limitation: FDA did not identify human exposure data for KPV given by any route and did not identify human KPV PK/PD studies. Human injectable dosing, pharmacokinetics, long-term safety and clinical efficacy therefore remain unknown, and no established human IBD dosing for KPV has been documented in an identifiable primary human study. Because human administration data are lacking, no clinically dominant human KPV receptor mechanism has been established; alpha-MSH relatedness is not a defined clinical target.
Specific chains such as MC1R activation leading to predictable vasodilation, melanocortin receptor activation leading to predictable pigmentation, or area postrema activation leading to predictable nausea are not established human KPV pharmacology.
- Pigmentation: not established as a KPV effect in humans.
- Blood-pressure effects: not established.
- Nausea: community-reported, with an uncertain mechanism.
There is no controlled human KPV dataset establishing a predictable first-week nausea period, blood-pressure pattern, injection welt mechanism or pigmentation response.
Infection, autoimmune disease and immunosuppression
KPV has anti-inflammatory effects in experimental models, but its effects on human infection, antimicrobial defense and post-infectious recovery have not been established. KPV has not been shown to suppress human antimicrobial defense, and KLOW is not an established post-infectious repair or maintenance treatment.
The clinical effects and safety of KPV in people with autoimmune disease or on immunosuppressive therapy have not been established. There is no evidence base for disease-specific KLOW use in IBD, psoriasis, lupus, vasculitis, rheumatoid arthritis or similar conditions.
BPC-157
BPC-157 has substantial preclinical research, but human evidence remains extremely limited. A two-person IV pilot exists, and newer reviews identify a small amount of additional uncontrolled human pilot experience. Overall, the human literature involves fewer than 30 people across very small uncontrolled studies, without a validated pharmaceutical formulation or an established Phase II efficacy program.
- BPC-157 preclinical evidence: substantial
- Human evidence: extremely limited, small uncontrolled pilots
- Human SC KLOW dose: not validated
- KLOW combination evidence: none established
GHK-Cu
GHK-Cu has legitimate biological research involving the extracellular matrix, collagen, wound biology, tissue remodeling and related signaling. That component biology does not establish chronic subcutaneous GHK-Cu or the four-component KLOW blend as clinically effective or safe. FDA states that compounded injectable GHK-Cu may present immunogenicity risk because of aggregation and peptide-related impurities, and that human safety data are limited.
Dopamine claims
"Dopamine buffer" is not a validated KLOW property. Fatigue or mood changes may appear in community reports, but KLOW has no controlled human safety dataset establishing their incidence, duration or mechanism, and fatigue or anhedonia are not established consequences of dopaminergic modulation by BPC-157, the thymosin component or KPV.
Independent evidence
| Evidence area | Rating |
|---|---|
| Exact KLOW blend | Very limited |
| Human KLOW efficacy trial | None identified |
| Human KLOW dose-finding | None identified |
| KLOW PK/PD | None identified |
| KPV preclinical evidence | Meaningful |
| KPV human exposure | FDA identified none |
| BPC-157 preclinical evidence | Substantial |
| BPC-157 human evidence | Extremely limited |
| Full-length Tβ4 human evidence | Limited but real |
| TB-500 LKKTETQ human exposure | FDA identified none |
| GHK-Cu biological evidence | Meaningful |
| Injectable GHK-Cu human safety | Limited; FDA concerns |
| 3.2 mg KLOW protocol | Community |
| 5 days on / 2 days off | Community convention |
| 2 to 4 to 6 to 4 mg titration | Community convention |
| Routine zinc | Unsupported |
| Dopamine-buffer claim | Unsupported |
| Same-vial stability | Not established |
| Universal 28-day beyond-use date | Not established |
| FDA-approved KLOW | No |
FDA 2026 regulatory context
FDA staff scientific evaluation, Pharmacy Compounding Advisory Committee activity, 503A Bulks List status and FDA drug approval are separate regulatory concepts. In its 2026 scientific evaluation, FDA staff concluded that the available evidence weighed against adding KPV free base and KPV acetate to the 503A Bulks List. The July 2026 advisory process is separate from FDA approval of a drug, and KPV remains an unapproved substance without established human clinical efficacy or safety. The same distinction applies to BPC-157 and TB-500: staff recommendations, advisory votes and list status are not drug approval or rejection.
Bottom line
KLOW is a community or vendor four-component blend, not a standardized or FDA-approved treatment. A common 80 mg formulation contains 50 mg GHK-Cu plus 10 mg each of BPC-157, KPV and a thymosin-related component, but the exact thymosin molecule must be confirmed. The commonly cited 3.2 mg dose is mathematically coherent for that formulation, but it is a community dose rather than a clinically validated treatment dose. The largest additional evidence limitation is KPV: it has meaningful laboratory and animal anti-inflammatory research, but FDA has not identified human KPV exposure data by any route. KLOW is best understood through component evidence, documented community protocols and explicit uncertainty about the exact blend.
Storage
No FDA-approved KLOW formulation establishes a universal reconstitution method, bacteriostatic-water volume, refrigerated shelf life, 14-day limit or 28-day limit. Same-vial chemical and physical stability must be established for the exact formulation.
A vendor selling four peptides in one vial shows that a product exists. It does not establish long-term peptide integrity, compatibility, potency retention, aggregation behavior or a validated beyond-use period. Community 28-day or other refrigerated-use windows are product or community handling conventions unless supported by exact-formulation stability data.
Contraindications & cautions
Formal contraindications
None are established, because there is no FDA-approved KLOW product or label.
Important cautions
| Caution | Classification |
|---|---|
| Copper metabolism disorders / Wilson disease | Strong biologically relevant caution |
| Pregnancy / breastfeeding | Safety unknown |
| Severe hepatic impairment | Important unknown / caution; the exact blend has not been adequately studied |
| Concurrent immunosuppressive therapy | Unknown / theoretical interaction |
| Active malignancy | Important theoretical and clinical caution, not an official absolute contraindication |
Several components influence repair, vascular or inflammatory pathways in experimental systems, but the effects of KLOW in active malignancy are unknown.
Possible side effects
Plausible or community-reported
- Injection-site pain or discomfort
- Redness
- Swelling
- Irritation
- Headache
- Nausea
- Fatigue
Exact incidence and causality are unknown because the fixed KLOW blend has not undergone a controlled human safety trial.
Not established as KLOW adverse effects
- Predictable pigment changes
- Predictable blood-pressure changes
- Zinc depletion
- Copper toxicity at a standard community dose
- Anhedonia
- Raised ALT/AST (not a normal expected KLOW effect)
Compatibility
Commonly paired with
No direct combination evidence shows that any of these pairings is synergistic.
| Pairing | Classification |
|---|---|
| Thymosin alpha-1 | Community / theoretical combination |
| LL-37 | Community / theoretical combination; LL-37 carries its own safety uncertainty |
| Matrixyl | Different use context; no established KLOW synergy |
Ingredient overlap and redundancy
| Combination | Overlap |
|---|---|
| KLOW + GLOW | Major ingredient duplication: GHK-Cu, BPC-157 and thymosin component |
| KLOW + KPV | Duplicates KPV |
| KLOW + BPC-157 | Duplicates BPC-157 |
| KLOW + GHK-Cu | Increases GHK-Cu and copper exposure |
| KLOW + TB-500 / Tβ4 | Potentially duplicates the thymosin component; the exact molecule must be checked |
| KLOW + Tri-Heal | Formula-dependent duplication |
These combinations are not pharmacologic contraindications in themselves. The main issue is duplicate ingredients and uncertain total exposure.
Sources
- U.S. Food and Drug Administration. 2026 KPV briefing document (no identified human KPV exposure data or human PK/PD studies). 2026.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (KPV, BPC-157, injectable GHK-Cu and TB-500). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- PubMed. KPV and PepT1 experimental literature (KPV anti-inflammatory biology and PepT1-related experimental transport).
- PubMed. BPC-157 human IV pilot study and current reviews (human BPC-157 evidence extremely limited). https://pubmed.ncbi.nlm.nih.gov/40131143/; https://pubmed.ncbi.nlm.nih.gov/40789979/
- Human full-length thymosin β4 wound literature (limited, route-specific human evidence). https://pubmed.ncbi.nlm.nih.gov/23050815/
- GHK-Cu reviews and human literature (component-level tissue-remodeling biology). https://pubmed.ncbi.nlm.nih.gov/29986520/
- PeptideFox. KLOW (community / practitioner source: 80 mg 50/10/10/10 formulation, 3.2 mg community example, full-length thymosin β4 terminology).
- PeptideDosages. KLOW (community source with a different total-blend dosing framework and TB-500 terminology).